Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17814183 | 0.92 | MAPK1 (0.41) | MAPK1PARP10PARP11CYP11B1CYP11B2 | |
| SCHEMBL17814186 | 0.84 | CYP11B1 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL17814101 | 0.84 | GSK3B (0.45) | MAPK1GSK3BCYP11B1CYP11B2MAPKAPK2 | |
| SCHEMBL17814179 | 0.83 | CYP11B1 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL17814143 | 0.82 | PARP10 (0.42) | MAPK1PARP10PARP11GSK3BCYP11B1 | |
| SCHEMBL17814093 | 0.79 | CYP11B2 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL17814122 | 0.79 | CYP11B1 (0.53) | CYP11B1CYP11B2 | |
| SCHEMBL21105107 | 0.78 | CYP11B1 (0.49) | CYP11B1CYP11B2 | |
| SCHEMBL17814176 | 0.77 | PDE3B (0.47) | CYP11B1CYP11B2TGFBR1ACVR1 | |
| SCHEMBL17814171 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | MAPK1 969/4885PARP10 871/4885PARP11 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.